查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗凝血劑市場：按藥物類別、應用、地區劃分——規模、份額、展望、機會分析，2022-2028 年
市場調查報告書
商品編碼
1213864

抗凝血劑市場：按藥物類別、應用、地區劃分——規模、份額、展望、機會分析，2022-2028 年

Anticoagulant Market, By Drug Class, By Application, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

抗凝劑是一種防止血液凝塊的藥物。 通常稱為血液稀釋劑。 它用於發生血栓的高風險人群，以減少出現嚴重症狀（如中風或心髒病發作）的機率。 抗凝劑通常用於預防和治療心血管疾病 (CVD)。

市場動態

全球慢性病流行、抗凝劑需求增加、新型抗凝劑開發重點以及老年人口增加預計將成為推動全球抗凝劑市場增長的主要因素。我來了。

例如，2022 年 6 月，Apotex 宣布推出 APO-Apixaban 片劑，這是加拿大首個 Eliquis 的仿製藥替代品。 阿□沙班是一種口服抗凝劑，用於預防和治療有害血栓。

此外，2021 年 6 月，美國食品藥品監督管理局 (FDA) 批准了 pradaxa（達比加群酯）口服微丸用於治療 3 個月至 12 歲兒童的靜脈血栓栓塞症。 FDA 還批准了 pradaxa 口服微丸用於預防 3 個月至 12 歲以下已完成初始靜脈血栓栓塞治療的患者的複發性血栓。

這項研究的主要特點

  • 本報告對全球抗凝劑市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2028 年）的市場規模和復合年增長率 (CAGR%) 的增長情況。
  • 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
  • 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
  • 全球抗凝劑市場主要參與者的概況基於以下參數，包括公司亮點、產品組合、主要亮點、績效和策略。
  • 參與這項研究的主要公司包括輝瑞公司、賽諾菲公司、雷迪博士實驗室、Aspen Holdings、Abbott Laboratories、Leo Pharma、Alexion Pharmaceuticals Inc.、拜耳公司、強生公司、百時美施貴寶公司、Daiichi Sankyo Company 和 Boehringer Ingelheim Pharmaceuticals Inc. 等。
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 《全球抗凝血劑市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球抗凝劑市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 市場概況：按藥物類別
    • 市場概況：按應用分類
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 全球慢性病發病率上升
    • 嚴格的政府法規
    • 對開發新型抗凝血劑的興趣日益濃厚
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章全球抗凝劑市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學
  • 供應方和需求方分析
  • 經濟影響

第 5 章全球抗凝劑市場：按藥物類別，2017-2028

  • 新型口服抗凝劑 (NOAC)
  • 肝素和低分子肝素 (LMWH)
  • 維生素 K 拮抗劑

第 6 章全球抗凝劑市場：按應用，2017-2028

  • 心房顫動/心肌梗塞（心髒病發作）
  • 深靜脈血栓形成 (DVT)
  • 肺栓塞
  • 其他用途

第 7 章全球抗凝劑市場：按地區劃分，2017-2028

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 世界其他地方

第八章競爭格局

  • Pfizer Inc.
  • Sanofi SA
  • Dr. Reddy's Laboratories
  • Aspen Holdings
  • Abbott Laboratories
  • Leo Pharma AS
  • Alexion Pharmaceuticals Inc.
  • Bayer AG
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Boehringer Ingelheim Pharmaceuticals Inc.

第 9 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5486

Anticoagulants are a class of drugs that help prevent blood clots. They are commonly called blood thinners. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. Anticoagulants are commonly used to prevent and treat cardiovascular diseases (CVDs).

Market Dynamics:

Growing prevalence of chronic disease, rise in demand for anticoagulants, increase in focus on the development of novel anticoagulants, and growing geriatric population across the globe are major factors expected to drive growth of the global anticoagulant market.

For instance, in June 2022, Apotex Inc. announced the launch of APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots.

Moreover, in June 2021, the Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets to treat children three months to 12 years old with venous thromboembolism. FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

Key features of the study:

  • This report provides in-depth analysis of the global anticoagulant market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global anticoagulant market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Sanofi SA, Dr. Reddy's Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global anticoagulant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulant market.

Detailed Segmentation:

  • Global Anticoagulant Market, By Drug Class:
    • Novel Oral Anticoagulants (NOACs)
    • Heparin and Low-molecular- weight Heparin(LMWH)
    • Vitamin K Antagonist
  • Global Anticoagulant Market, By Application:
    • Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • Deep Vein Thrombosis (DVT)
    • Pulmonary Embolism
    • Other Applications
  • Global Anticoagulant Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer Inc.
    • Sanofi SA
    • Dr. Reddy's Laboratories
    • Aspen Holdings
    • Abbott Laboratories
    • Leo Pharma AS
    • Alexion Pharmaceuticals Inc.
    • Bayer AG
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company
    • Boehringer Ingelheim Pharmaceuticals Inc.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Application
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Growing prevalence of chronic diseases across the globe
    • Stringent government regulations
    • Rise in focus on the development of novel anticoagulants
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Anticoagulant Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Anticoagulant Market, By Drug Class, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Novel Oral Anticoagulants (NOACs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Heparin and Low-molecular- weight Heparin (LMWH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Vitamin K Antagonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Anticoagulant Market, By Application, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Deep Vein Thrombosis (DVT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Pulmonary Embolism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Applications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Anticoagulant Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr. Reddy's Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aspen Holdings
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Leo Pharma AS
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Alexion Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Daiichi Sankyo Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us